Voxilaprevir (GS-9857) 是一种含氟大环丙型肝炎病毒 (HCV) 非结构蛋白 (NS) 3/4A 蛋白酶抑制剂。对基因型 1-6 HCV 具有很强的体外抗病毒活性，并广泛覆盖 NS3/4A 蛋白酶多态性。GS-9857 提高了对常见的 NS3 抗药性相关突变体 (RAVs) 的覆盖率。
CAS：1535212-07-7
分子式：C40H52F4N6O9S
分子量：868.93
纯度：98%
存储：Store at -20°C

Background:

Voxilaprevir (GS-9857) is a fluorinated macrocyclic hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms. GS-9857 improves coverage against commonly encountered NS3 resistance-associated variants (RAVs)[1][2]. Hepatitis C virus (HCV) nonstructural protein (NS) 3/4A protease[1]

[1]. Rodriguez-Torres M, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat. 2016 Aug;23(8):614-22. [2]. Lawitz E, et al. Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C VirusInfection in an Open-Label, Phase 2 Trial. Gastroenterology. 2016 Nov;151(5):893-901.e1.